Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SNV1521

Small molecule · Inhibitor of poly(ADP-ribose) polymerase 1 (PARP1)

Phase 1 Most advanced trial
1 Registered trials

What is SNV1521?

SNV1521 is an orally bioavailable inhibitor of PARP1, a nuclear enzyme that repairs damaged DNA. By blocking PARP1 activity, it prevents base excision repair, leading to accumulation of DNA strand breaks and apoptosis. It is being studied in combination with the RAS inhibitor daraxonrasib in pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
poly(ADP-ribose) polymerase 1 (PARP1)
Mechanism
Inhibitor of poly(ADP-ribose) polymerase 1 (PARP1)
Pathways
base excision repair, DNA single-strand break repair, double-strand break repair, apoptosis
Therapy area
Oncology
In trials of
RVMD
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07756281 Phase 1 Pancreatic Cancer Recruiting RVMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic Acinar CarcinomaPancreatic Cancer

Other drugs acting on PARP1

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.